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Summary 
In countries with low tuberculosis (TB) incidence, TB is concentrated in vulnerable 
populations, including people living with HIV (PLHIV) who have a substantially greater risk of 
TB than people without HIV. 
We searched PubMed, EMBASE and Web of Science for studies evaluating risk 
factors for latent TB infection (LTBI) or active TB in PLHIV in countries with TB incidence 
≤10/100,000 population. Due to the number of risk factors evaluated and heterogeneity in 
study designs, we present summary data and a narrative synthesis. 
We included 45 studies; 17 reported data on risk factors for LTBI and 32 on active 
TB. Black, Asian or Hispanic ethnicity, birth or long-term residence in a country with high TB 
incidence, and HIV acquisition via injecting drug use or heterosexual sex were strong 
predictors of both LTBI and active TB. History of contact, a greater degree of 
immunosuppression at diagnosis or higher viral load increased TB risk. 
Early HIV diagnosis to allow timely initiation of anti-retroviral therapy is essential for 
the prevention of TB in PLHIV. Screening and treating PLHIV for LTBI, to reduce risk of 
progression to active TB disease, should also be considered to further decrease the burden 
of active TB in low TB-incidence settings. Research to support the expansion of TB and HIV 
prevention and treatment globally is essential to eliminate TB in low-incidence settings. 
Key words: tuberculosis, HIV, co-infection, low incidence countries, risk factors 
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Introduction 
HIV is an important risk factor for tuberculosis (TB) disease; globally, people living 
with HIV (PLHIV) are at an estimated 26-31 times higher risk of TB than people without HIV 
infection.1 HIV co-infection is associated with higher rates of progression from latent to active 
TB, more severe disease presentation, worse clinical outcomes and increased mortality. An 
estimated 12.5% of new TB cases in 2014 were among PLHIV and TB is the leading cause 
of death for PLHIV; responsible for around one third of deaths.2 Globally, HIV-associated TB 
(HIV-TB) is concentrated in sub-Saharan Africa, which accounted for around three quarters 
of HIV-TB morbidity and mortality in 2015.3 HIV-TB co-infection also remains a persistent 
public health problem in low TB incidence countries (defined by the World Health 
Organization [WHO] as less than 10 cases per 100,000 population),4 where the changing 
epidemiology of TB has led to a concentration of disease in high risk groups. In 2012, an 
estimated 155,000 people fell ill with TB in low-incidence countries and 10,000 people died.5 
TB transmission in the general population in low-incidence countries is generally 
minimal, with the majority of cases occurring in patients born abroad as a result of 
progression from previously acquired latent infection.6 In addition to PLHIV, there is a 
disproportionate burden of TB among vulnerable populations such as recent migrants 
(particularly those from countries with high TB incidence) and people who are homeless, 
incarcerated, or have problems with substance abuse.5 These sub-populations are often 
referred to as “hard to reach”, linked by poverty, social deprivation and difficulties accessing 
healthcare.7 
Priority areas of the WHO’s action framework for TB in low-incidence countries 
include addressing TB in the most vulnerable and hard-to-reach groups, screening for latent 
and active TB in high-risk groups and ensuring continued patient-level surveillance and 
evaluation.4 There is considerable overlap between these at-risk groups, as many people 
have multiple risk factors, and/or difficulties accessing healthcare services. Systematic 
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screening of PLHIV for active TB is recommended, but is not done in all low-incidence 
countries.4 Systematic screening for LTBI is also recommended for PLHIV and other high-
risk groups, but not widely implemented.4 
Efforts to control HIV-TB are hampered by the significant proportion of PLHIV who 
are undiagnosed, diagnosed late, or not diagnosed until they present to healthcare service 
with other opportunistic infections such as TB. Managing TB in PLHIV is also more clinically 
complex, as a result of side effects of treatment, drug-drug interactions, and often a more 
severe presentation of disease.8 Preventing TB in PLHIV is therefore of paramount 
importance. However diagnosing LTBI in PLHIV can be difficult, as diagnostic tests for LTBI 
(particularly the tuberculin skin test [TST]) are less sensitive at low CD4 counts.9 
Furthermore, pressure on resources, even in countries with low TB incidence, necessitates 
the targeting of preventative activities such as screening for LTBI and active TB. It is 
therefore critical to have a clear insight into risk factors for TB disease in PLHIV in countries 
with low TB incidence. This review provides an up-to-date synthesis of the evidence on risk 
factors for LTBI and TB disease among PLHIV.  
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Methods 
We systematically searched PubMed, EMBASE and Web of Science on 4th May 
2017 for articles on risk factors for LTBI or active TB disease among people living with HIV in 
countries with low TB incidence (defined as ≤10 cases per 100,000 population, based on 
2015 WHO data).4 The search terms included variations of “tuberculosis”, “HIV” and the low-
incidence countries; full details of the search strategy and results are shown in Appendix 1. 
We excluded studies presenting data on multi-country cohorts if any country contributing to 
the cohort did not have low TB incidence. No limits were placed on year or language of 
publication. 
The search results were de-duplicated and screening was done by title, abstract and 
then full-text, by two reviewers (JW and AA) with 10% overlap. Any disagreements were 
resolved by consensus. The reference lists of included articles and relevant review articles 
were screened for additional papers. We provide a narrative synthesis of our findings. The 
review was registered on PROSPERO (CRD42017069544). 
Findings and Implications 
Search results and included studies 
After de-duplication, the search yielded 5,804 results. After title, abstract and full-text 
screening, 45 studies were included (Figure 1). Initial reviewer agreement was 99.3%, 
resolved to 100% after comparing the discrepant papers against the inclusion criteria. Of the 
45 included studies (summarised in detail in supplementary table 1), 17 provided data on 
risk factors for LTBI,10-26 32 included data on risk factors for active TB,23-54 and 4 studies 
contained data on both.23-26 The studies spanned the period 1977-2014. Risk factors for 
LTBI are summarised in Table 1 and risk factors for active TB disease are summarised in 
Table 2. 
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Sociodemographic factors associated with tuberculosis 
Sex 
Globally, the risk of TB is higher for men than women,55  however data on the effect 
of sex on risk of TB among PLHIV in this review were mixed. Of the nine studies which 
reported no association between sex and risk of LTBI, none adjusted for other factors such 
as route of HIV infection, which may have biased associations of risk of TB towards women; 
people who acquire HIV through heterosexual sex usually have higher rates of TB than 
MSM, as black African ethnicity and birth in countries with high TB incidence can be 
confounders for route of HIV infection. The HIV epidemic in sub-Saharan Africa 
disproportionately affects women, whilst the Western epidemic has predominantly affected 
men who have sex with men. As HIV-TB in low-incidence settings is mainly an issue for 
migrants from high-incidence countries, the higher number of heterosexual women than men 
diagnosed with HIV affects that observed patterns of HIV-TB. 
Ethnicity and Country of Birth 
We found that the risk of both LTBI and active TB was greatest among PLHIV from 
ethnic minorities; particularly those of black African, South Asian or Hispanic 
ethnicity.13,15,17,19,23,25,31,32,37,43,44,46,49,52,53 Similarly, PLHIV who were born in, or long-term 
residents of, countries with high TB incidence had higher rates of LTBI and active TB.10-
13,17,18,22-24,26,45,56 Few studies examined the effects of country of birth and ethnicity 
independently of each other; those that did found no independent associations between 
ethnicity and country of birth and active TB34,46 or LTBI.14,17 However, a more recently 
published study stratified the risk of developing active TB by ethnicity and the TB incidence 
in country of birth and demonstrated that ethnicity and the incidence of TB in the patient’s 
country of birth independently increase the risk of developing TB for PLHIV. TB incidence 
among black African PLHIV born in high-incidence countries was higher than that of PLHIV 
with only one of these risk factors.57 Both ethnicity and country of birth are proxy measures 
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for long-term exposure to TB; visiting a TB-endemic country was not associated with the risk 
of LTBI, although the association between the length of visit and risk of LTBI was not 
explored.45 
One study observed that the risk of TB among migrants decreased with increasing 
time since entry to the country. This could reflect reversion of previously acquired infection, 
as the risk of LTBI in PLHIV born abroad decreased with time since migration.45 It could also 
be attributed to the fact that there is an increased risk of TB amongst people who were 
infected with HIV abroad,46 and that the likelihood of HIV infection remaining undiagnosed 
decreases with time, and therefore the risk of TB decreases as patients become aware of 
their HIV infection and initiate ART.  This is supported by the fact that the risk of active TB 
increased with increasing time from entry to the study country to HIV diagnosis.41 As the 
majority of PLHIV born abroad are likely to have been infected with HIV in their country of 
birth,58 the increased risk of TB with time from migration to HIV diagnosis is likely a reflection 
of late HIV diagnosis and low CD4 count. 
Route of HIV infection  
Both LTBI and active TB were more likely to occur in study participants who acquired 
their HIV infection through heterosexual sex, injecting drug use or mother-to-child 
transmission than by sex between men, and having a partner who injected drugs was also 
associated with increased risk of LTBI.15,19,24,26,31,32,34,35,38,41,51 Children with TB were more 
likely to have mothers who acquired HIV through injecting drug use than heterosexual sex or 
other routes of transmission, compared to HIV-infected children without TB.52 Injecting drug 
use was associated with increased risk of TB,33,43,49 as was long term tobacco use,39 
however alcohol misuse was not.59 It is likely that routes of HIV infection other than sex 
between men are confounders for exposure to TB, which was an important risk factor for 
both LTBI and active TB, but one which few studies examined directly. In particular, HIV 
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acquisition through heterosexual sex is strongly correlated with birth in countries with high 
TB incidence,60 discussed previously. 
Other social risk factors 
Homelessness, and living or working in a collective group or institution, were 
associated with higher risks of LTBI,10,13,18,19 Proximity to persons with TB was also 
important; close contact with a TB case increased the risk of LTBI10,11,19,21,45 and active 
TB,25,29,40 and a study set in a prison demonstrated that closer proximity was associated with 
increased risk.25 
Clinical risk factors for HIV-TB 
CD4 count, viral load and ART 
CD4 counts of <500 cells/µl were overwhelmingly inversely associated with greater 
risk of developing active TB.23,24,27,28,30,31,33-38,42-44,46,49-51 ART was highly protective against 
active TB for PLHIV,24,27,30,34,35,46,51 with a time-dependent decrease in risk of TB during ART 
documented in multiple studies.27,31,43,44 Conversely, though the data were conflicting, high 
viral loads were associated with increased risk of active TB in most studies.27,31,32,35,36 
Together, these findings highlight the fundamental importance of early diagnosis and 
treatment of HIV in preventing HIV-TB. As recommended in existing guidelines, this may 
require screening programmes to be implemented in groups of people at high risk.  
LTBI 
Anergic patients and patients with a positive TST result had significantly higher risk of 
TB than TST-negative and/or non-anergic patients.24,28,30,38,47,48 However, diagnosing LTBI in 
PLHIV is challenging, particularly among those with low CD4 counts. There was no 
consistent association with the risk of LTBI for CD4 count, HIV viral load, or ART. Low CD4 
count was not associated with an increased risk of LTBI among PLHIV, 10-12,17,22 and some 
studies (particularly those which used TSTs to diagnose LTBI) reported higher rates of LTBI 
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in participants with high CD4 counts.14,16,24,26 This is likely due to lower sensitivity of 
diagnostic tests for LTBI at lower CD4 counts, which is well documented for TSTs but less 
so for interferon-gamma release assays (IGRAs). This difficulty diagnosing LTBI at low CD4 
count means that it is not established as to whether HIV increases the risk of becoming 
infected with TB (as opposed to progression to active disease, the evidence for which is 
definitive). Known LTBI was associated with increased risk of TB disease, 24,28,30,38,47,48 
although this risk was lessened by preventive therapy.24,26,47 A longer duration of preventive 
therapy was more protective.48 The difficulty diagnosing LTBI at low CD4 counts means that 
preventive TB therapy for PLHIV at high risk of exposure to pulmonary TB patients is 
important, since low CD4 counts can prevent diagnosis of LTBI and there is a high risk of 
progression to active TB if latent infection is established.  
History of previous TB 
Two studies examined the relationship between prior active TB disease and the risk 
of active TB; an observational cohort reported that prior TB was associated with higher risk 
of TB,28  however a study in a prison of an outbreak which occurred as a result of infection 
from a single source patient found no association between prior TB and risk of TB. This may 
suggest that prior TB increases the risk of active TB either because it is a marker for other 
risk factors relating to risk of exposure to TB or progression from LTBI to active TB. These 
factors could include higher background rates of TB, low CD4 count, unsuccessful treatment 
of prior disease or development of drug resistance during treatment of the previous disease.  
Strengths and limitations of the study design and findings 
The systematic search strategy enabled a comprehensive review of the literature. 
Due to the high number of records found by our search, 10% of results were screened by 
two reviewers. Between-reviewer agreement was high and the discrepant articles were 
generally excluded after reviewing them against the inclusion criteria. Accordingly, our 
strategy demonstrated a high sensitivity. 
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For the purposes of our inclusion criteria, countries were defined as ‘low incidence’ 
based on the TB incidence of TB in 2015; this was a pragmatic choice as many studies 
spanned several years and TB incidence changed over time. Consequently we may have 
included studies from periods where the TB incidence was above 10/100,000 population, or 
excluded studies conducted where TB incidence was less than 10/100,000 prior to 2015 but 
not in 2015. This is particularly relevant for small countries, where a small change in the 
number of cases reported could result in a substantial fluctuation in incidence. We excluded 
multi-country studies where not all the countries had low TB incidence and data were not 
presented stratified by country, which led to the exclusion of some large studies of active TB 
incidence among PLHIV. However, the findings of these studies were consistent with those 
of this review; the HIV-CAUSAL study, the EuroSIDA cohort and the ART Cohort 
Collaboration reported that higher TB incidence was associated with low CD4 count, high 
viral load, HIV acquisition by injecting drug use or heterosexual sex (compared to MSM), and 
being born in Africa.61-64 
We did not report on the magnitude of associations between the various risk factors 
and LTBI or active TB due to the considerable heterogeneity in the design and statistical 
analyses of the included studies, particularly variation in how variables were categorised, 
which category was used as the baseline, and which other variables (if any) were adjusted 
for. There were no clear differences in the directions of associations between risk factors 
and the outcome in studies which conducted multivariable analyses and those which only 
reported univariable associations; accordingly, this does not appear to be a source of bias. 
The majority of studies were large cohorts or utilised national surveillance data and so would 
have used standard definitions for active TB, although this was generally not stated 
specifically. 
The majority of the literature included in this review was from Western Europe and 
North America. The risk factors for TB in PLHIV discussed here may therefore not be 
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generalisable to other low-incidence settings with different migration patterns, such as 
Australia. Many of the risk factors for TB identified in this study will also apply to people who 
are not infected with HIV. In particular, people born in countries with high TB incidence have 
high rates of TB even without HIV infection. Consequently, incorporating HIV testing and 
care into screening programmes targeted to those at high risk of TB is important to ensure 
that preventive measures are being offered to all those with a high risk of TB. 
Opportunities for Prevention 
Early HIV diagnosis and ART initiation 
Early diagnosis of HIV is fundamental to the prevention of HIV-TB, as early initiation 
of ART is highly protective against TB disease. Early diagnosis of HIV also provides an 
opportunity to test and treat PLHIV for LTBI before active TB can develop. However, there 
are challenges at all stages of the continuum of HIV care; diagnosing HIV, linking patients to 
HIV care, initiating ART, and viral suppression. This highlights the importance of the 
UNAIDS 90-90-90 targets.65 Despite the UK exceeding the overall UNAIDS target for the 
proportion of PLHIV that are virally suppressed, a substantial number of TB diagnoses in 
PLHIV are in people who are not aware of their HIV infection prior to their TB diagnosis.46,57  
Scale-up of targeted HIV testing of populations at high risk of both HIV and TB disease such 
as migrants from high-burden countries and people who inject drugs may facilitate earlier 
diagnosis of HIV, which may allow prevention of many cases of TB among these 
populations. 
HIV testing could also be incorporated alongside screening initiatives for other 
diseases with overlapping risk profiles, including TB, hepatitis B and C. These may including 
active case finding programmes targeting vulnerable groups (including the homeless, 
prisoners, high-risk drug users and migrants).66 One study found that HIV-positive children 
with TB were more likely to have mothers who acquired HIV through injecting drug use than 
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through heterosexual sex or other routes of transmission than HIV-positive children without 
TB. This suggests that antenatal HIV screening and preventive treatment for TB are not 
being effectively delivered to “hard to reach” women who acquired HIV infection through 
injecting drug use, resulting in a higher risk of TB for their children than for the children of 
heterosexual women with HIV. Improving support to access antenatal HIV screening could 
help prevent mother-to-child HIV transmission in hard to reach populations and reduce the 
susceptibility of mothers and their children to TB. 
Pre-entry screening of migrants from countries with high TB incidence for pulmonary 
TB is now required for migrants moving to the UK, Australia, Canada, New Zealand and the 
USA, and other countries could consider adopting these guidelines to reduce the incidence 
of active TB. However, this strategy cannot prevent TB among migrants who arrive via 
irregular routes (who may be among those at highest risk of disease), and pre-entry 
screening does not include testing for LTBI or HIV. Promoting integrated screening for HIV 
infection and LTBI to migrants from countries with high TB incidence, particularly those who 
have recently entered the country, could also be an effective measure to both diagnose HIV 
sooner and prevent LTBI from progressing into active TB disease. 
LTBI testing and treatment for PLHIV 
Recent clinical trials in high TB-incidence settings have demonstrated the efficacy of 
isoniazid preventive therapy for reducing TB incidence among PLHIV.67 However, in low-
incidence settings, there are challenges in determining who should be offered preventive 
therapy, and in increasing uptake of testing and treatment for LTBI.68 In low-incidence 
settings, the WHO recommend systematic testing for and treatment of LTBI among PLHIV,4 
prioritising those with recent infection, and those who have recently migrated from high- to 
low-burden settings. National guidelines have followed suit, with the CDC recommending 
testing all PLHIV for LTBI at the time of HIV diagnosis, and treating those who test positive 
or who are close contacts of infectious pulmonary TB patients.69 For PLHIV who are 
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diagnosed with HIV with a CD4 count <200 cells/µl, the CDC also recommend re-testing for 
LTBI once the CD4 count has risen to ≥200.69 Similarly, the UK recommend screening 
PLHIV for LTBI according to criteria based on CD4 count, time on ART, and country of 
birth;70,71 however, these guidelines are not widely implemented.68 Further research is 
required to understand whether the barriers to testing and treating LTBI are occurring at the 
clinic level (i.e., whether testing and treatment for LTBI are being offered) or at the patient 
level, and how these barriers can be overcome to improve the uptake of LTBI testing and 
treatment.  
Systematic screening for active TB 
The WHO recommend screening for active TB in high-risk groups, such as PLHIV, 
due to both the high risk of developing TB and the high likelihood of severe consequences if 
TB diagnosis and treatment are delayed.4 Earlier diagnosis of active TB as a result of 
screening programmes may also reduce onwards transmission. General WHO guidance on 
systematic screening for active tuberculosis includes a strong recommendation to screen 
PLHIV for active TB at each visit to a health facility.72 In low-incidence settings (where the 
majority of PLHIV are receiving ART and virologically suppressed), this is unlikely to be an 
efficient use of resources; indeed the WHO action framework for low-incidence countries4 
does not specify the frequency at which PLHIV should be screened for active TB. The risk of 
TB has been shown to decrease over time following HIV diagnosis,27,35,57 therefore screening 
for active TB at, or soon after, HIV diagnosis may be the most efficient use of resources. 
Cost-effectiveness analyses would be useful to investigate the efficacy and impact of such 
screening programmes, to inform guidelines. 
Conclusions 
Important sociodemographic risk factors for HIV-TB include black African ethnicity, 
birth in a country with high TB incidence (particularly sub-Saharan Africa) and HIV 
acquisition through injecting drug use. Clinical risk factors for HIV-TB include low CD4 count, 
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high viral load and failure of (or late) initiation of ART. This highlights a number of critical 
opportunities for the prevention of HIV-TB in low TB-incidence settings. These include early 
HIV diagnosis and timely initiation of effective ART, testing and treatment of PLHIV for LTBI, 
along with prompt diagnosis and treatment of those who develop HIV-TB. 
TB ultimately cannot be eliminated in low-incidence countries without addressing the 
global epidemic of HIV-TB. While considerable progress has been made in the main 
approaches to manage HIV infection, there remain considerable challenges in 
implementation and programmatic research even in high income settings. Research to 
support more rapid expansion of HIV diagnostics globally including self-testing, measures to 
ensure the scaling-up of access to ART to the nearly 17 million PLHIV currently not on 
treatment, and approaches to deliver isoniazid preventative therapy for PLHIV are crucial to 
global HIV-TB control efforts. Furthermore, TB-HIV programmes should ensure better 
access to ART for pre- and post-exposure prophylaxis, effective needle exchange 
programmes, and support a wider range of community interventions promoting behaviour 
changes to prevent HIV. 
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Figure 
Figure 1: Flow chart of the screening process and included studies 
 
 
 
Tables 
  
8,457 results from all databases 
5,804 after de-duplication 
45 included after full-text screening 
408 included after abstract screening 
1,099 included after title screening 
4,705 excluded: 
Irrelevant to search criteria 
691 excluded: 
Irrelevant to search criteria 
363 excluded: 
142 not conducted solely in low-incidence setting 
138 no data on risk factors 
53 not original research 
47 all patients had TB 
19 outcome not TB 
9 study population was not PLHIV 
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Table 1 
Table 1: Summary of risk factors for latent tuberculosis infection among people living with HIV 
Risk factor for LTBI Summary of results 
Sociodemographic 
factors 
 
Age Greater risk with increasing age: 1 study  19 
QFT-GIT-positive participants were significantly younger than 
QFT-GIT-negative participants: 1 study 11 
No association: 11 studies 10,12,13,16-18,21-24,45 
Ethnicity Greater risk for black participants than white participants: 4 studies 
15,17,19,23 
Greater risk for Asian participants than white participants: 2 studies 
13,17 
Greater risk for Hispanic participants than white participants: 1 
study 15 
No association: 2 studies 18,22 
Country of birth or 
residence 
Greater risk of LTBI in participants who were born abroad: 4 
studies 13,21,23,24 
Greater risk of LTBI in participants born in Africa: 3 studies 23,24,26 
Greater risk for participants who were born or long-term residents 
in countries with high TB incidence: 7 studies 10-12,17,18,22,45 
Risk of TB decreased with time since migration:  1 study 45 
No association with visiting a TB-endemic country: 1 study  45 
Sex Greater risk for women: 2 studies 10,23 
Greater risk for men: 1 study 24 
No association: 9 studies 11-13,15-18,22,45 
Single-sex studies: 4 studies 14,19,21,25 
Pregnancy No association: 1 study 19 
All participants were pregnant: 1 study 21 
Route of HIV infection Higher rates of TST positivity among people who inject drugs 
and/or have a partner who injects drugs: 2 studies 15,24 
Higher rates of TST positivity among people who acquired HIV 
through heterosexual sex than by sex between men: 1 study 24 
Significant, but not described, differences in risk by infection route: 
1 study 26 
No association: 2 studies 22,23 
Drug misuse Higher rates of illicit drug use amongst TST-positive participants 
than TST-negative participants: 1 study 19 
No association between injecting or recreational drug use and 
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Risk factor for LTBI Summary of results 
LTBI: 8 studies 11-13,16,18,21-23 
Alcohol misuse No association: 2 studies 11,13 
Homelessness Greater risk among those who were homeless, or lived in 
group/institutional living or a homeless shelter: 3 studies 10,13,19 
No association: 3 studies 12,18,22 
Imprisonment No association: 4 studies 12,13,19,22 
All participants were in prison: 1 study 25 
Contact with TB, or other 
close exposure to TB 
Greater risk for those living or working in a homeless shelter, 
prison or drug rehabilitation unit: 1 study 18 
Greater risk for participants with a contact with TB or smear-
positive TB: 5 studies 10,11,19,21,45 
Greater risk for prisoners closer to the source patient of an 
outbreak within a prison: 1 study 25 
No association: 2 studies 12,18 
Level of education No association: 1 study 19 
Income No association between income and LTBI: 1 study 19 
No association between receiving public social aid and LTBI: 1 
study 22 
Occupation No association: 1 study 12 
Clinical factors  
CD4 count and DTH result Higher rates of LTBI at higher CD4 counts: 7 studies 13,16,22-24,26,45 
No association between CD4 count and LTBI: 7 studies 10-
12,14,17,18,25 
No association between a positive DTH reaction and LTBI: 1 study 
16 
Viral load Greater risk with high viral load: 1 study 23 
Lower risk with viral load: 1 study 24 
No association: 9 studies 10-14,16,18,22,25 
Anti-retroviral therapy Lower risk of LTBI for participants on ART: 3 studies 14,23,24 
No association: 8 studies 11,12,17,18,22,25,26,45 
All patients were on ART: 1 study 16 
BCG vaccination No association: 2 studies 10,18 
Previous TB disease Greater risk of LTBI for patients with prior active TB disease: 6 
studies 10,11,18,22,23,45 
Latent tuberculosis 
infection 
Greater risk of current LTBI for patients with a history of LTBI: 2 
studies 10,18 
Previous treatment for 
LTBI 
Participants with LTBI were more likely to have been previously 
treated for LTBI: 1 study 18 
25 
 
 
Risk factor for LTBI Summary of results 
AIDS-defining illness Higher risk of LTBI for patients with prior AIDS: 1 study 22 
No association: 4 studies11,16,21,45 
Other non-infectious co-
morbidities 
No association between diabetes and LTBI: 1 study 11 
Time since HIV diagnosis 
or duration of follow-up 
time 
No association: 4 studies 11,21,22,45 
AIDS: acquired immunodeficiency syndrome. ART: anti-retroviral therapy. BCG: Bacillus 
Calmette-Guérin. DTH: delayed-type hypersensitivity. LTBI: latent tuberculosis infection. QFT-
GIT: quantiFERON-gold in-tube. TB: tuberculosis. TST: tuberculin skin test. 
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Table 2 
Table 2: Summary of risk factors for active tuberculosis disease among people living with HIV 
Risk factor for 
active TB 
Summary of results 
Sociodemographic 
factors 
 
Age Risk increases with age: 2 studies 33,41 
Risk decreases with age: 1 study 26 
Risk was highest in the middle age categories: 3 studies 32,53,54 
No association: 17 studies 24,27-31,34-37,42-44,46,49-51 
Ethnicity Greater risk for black or black African participants than white participants: 
10 studies 25,31,32,37,43,44,46,49,52,53 
Greater risk for Asian participants than white participants: 3 studies 32,46,53 
Greater risk for Hispanic participants: 2 studies 49,53 
No association: 4 studies 34,36,38,54 
Country of birth or 
residence 
Greater risk among participants who were born or acquired HIV abroad: 8 
studies 26,27,34,43,44,46,53,54 
Greater risk among participants from Africa: 5 studies 24,27,33,35,51  
Greater risk among participants from Asia: 2 studies 33,51 
Greater risk among participants from South America: 1 study 33  
Greater risk for participants from countries with higher TB incidence: 2 
studies 36,50 
Risk of TB increased with time since arrival for foreign-born participants: 
1 study 41 
No association: 2 studies 23,30 
Region Risk of TB varied by region of country: 1 study 27 
No association: 4 studies 28,30,38,54 
Sex Greater risk for men: 5 studies 34,41,44,46,47 
Greater risk for women: 2 studies 26,52 
No association: 15 studies 24,28-30,32,35,37,38,42,43,49-51,53,54 
Risk presented grouped with route of HIV infection: 2 studies 27,31 
Single-sex studies: 1 study 40 
Route of HIV 
infection 
Greater risk for people who acquired HIV through heterosexual sex than 
from sex between men: 7 studies 27,31,32,34,41,44,51 
Greater risk for people who acquired HIV infection through injecting drug 
use than from sex between men: 5 studies 27,32,34,41,51 
Greater risk for people who acquired HIV through mother-to-child 
transmission than from sex between men: 1 study 32 
Greater risk among children with mothers who acquired HIV through 
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Risk factor for 
active TB 
Summary of results 
injecting drug use: 1 study 52 
No association: 7 studies 24,26,28,30,35,38,50 
All participants were heterosexual: 1 study 46 
Drug misuse Greater risk for participants who inject drugs: 3 studies 33,43,49 
Greater risk for participants who used tobacco long-term: 1 study 39 
No association: 1 study 29 
All participants had a history of prior or current drug use: 2 studies 39,47 
Alcohol misuse No association: 1 study 51 
Imprisonment All participants were in prison: 2 studies 25,40 
Level of education No association: 1 study 38 
Clinical factors  
Year of diagnosis Greater risk among those who entered the cohort later: 1 study 27 
Greater risk of TB if diagnosing with HIV during the ART era than prior to 
ART being introduced: 1 study 41 
No association: 3 studies 31,51,54 
CD4 count Greater risk at lower CD4 count: 22 studies 23,24,27,28,30-38,40,42-44,46,49-52 
No association: 3 studies 25,26,39 
Viral load Greater risk with higher viral load: 9 studies 23,24,27,31,32,35,36,43,44 
No association: 6 studies 25,34,37,49,51,54 
Anti-retroviral 
therapy 
Lower risk for patients on ART: 10 studies 23,24,27,30,34,35,43,44,46,51 
Lower risk with increasing time on ART: 4 studies 27,31,43,44 
No association: 7 studies 25,26,28,36,37,49,54 
All patients were on ART: 1 study 32 
Previous TB 
disease 
Greater risk for patients with a history of TB: 1 study 28 
No association: 1 study 40 
LTBI infection and 
anergy 
Greater risk for patients with known LTBI: 6 studies 24,28,30,38,47,48 
Greater risk for anergic patients: 1 study 28 
No association: 1 study 40 
Previous treatment 
for LTBI 
Lower risk for patients who had been treated for LTBI: 4 studies 24,26,47,48 
No association: 2 studies 34,40 
Contact with TB or 
other close 
exposure to TB 
Greater risk for patients who had been exposed to active TB: 3 studies 
25,29,40 
AIDS-defining 
illness or other 
opportunistic 
infections 
Greater risk for patients with prior AIDS: 2 studies 27,34 
Greater risk for patients with more clinical symptoms of AIDS: 1 study 23 
28 
 
 
Risk factor for 
active TB 
Summary of results 
No association: 4 studies 28-30,54 
Lower risk for patients taking prophylactic co-trimoxazole: 1 study 33 
Time since HIV 
diagnosis or 
duration of follow-
up time 
Decreasing risk over time: 2 studies 27,35 
Greater risk for patients with more follow-up time: 1 study 50 
No association: 1 study 37 
AIDS: acquired immunodeficiency syndrome. ART: anti-retroviral therapy. BCG: Bacillus 
Calmette-Guérin. LTBI: latent tuberculosis infection. QFT-GIT: quantiFERON-gold in-tube. TB: 
tuberculosis. TST: tuberculin skin test.
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